Motif Bio Conference Call and Webcast
February 19 2019 - 2:00AM
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage
biopharmaceutical company specialising in developing novel
antibiotics, today announced that the Company will hold a
conference call
on Tuesday, February 19, 2019 at 8:30 AM
ET/1:30 PM GMT/2:30 PM CET. The call will be held to
discuss recent events that Motif has announced and the Company’s
plans.
No new material information will be disclosed
during the call.
The dial-in details are as follows:
United Kingdom: |
+44 (0)20 3107 0289 |
|
|
Germany: |
+49 (0) 69 2222 4703 |
|
|
United States: |
+1 703-736-7410 or |
|
+1 866-219-5264 |
Please dial in ten minutes in advance of the call and refer to
Conference ID 6261269.
The call will also be webcast. Please visit the Investors,
Events and Presentations section of Motif Bio’s website at
http://ir.motifbio.com/phoenix.zhtml?c=254416&p=irol-calendar
for a link to the webcast.
For further information please contact:
Motif Bio plc |
ir@motifbio.com |
Graham Lumsden (Chief Executive Officer) |
|
|
|
Peel Hunt LLP (NOMAD &
BROKER) |
+ 44 (0)20 7418 8900 |
Dr Christopher Golden |
|
Oliver Jackson |
|
|
|
Walbrook PR Ltd. (UK FINANCIAL PR &
IR) |
+44 (0)20 7933 8780 |
Paul McManus/Helen Cresswell/Lianne
Cawthorne |
motifbio@walbrookpr.com |
|
|
MC Services AG (EUROPEAN
IR) |
+49 (0) 89 210 2280 |
Raimund Gabriel |
raimund.gabriel@mc-services.eu |
|
|
Russo Partners (U.S. PR) |
+1 (858) 717-2310 or +1 (212) 845 4272 |
David Schull |
david.schull@russopartnersllc.com |
Travis Kruse, Ph.D. |
travis.kruse@russopartnersllc.com |
Note to Editors:
About Motif BioMotif Bio plc
(AIM/NASDAQ: MTFB) is a clinical-stage biopharmaceutical company
focused on developing novel antibiotics designed to be effective
against serious and life-threatening infections caused by
multi-drug resistant Gram-positive bacteria, including MRSA. The
Company’s lead product candidate is iclaprim. Motif Bio is seeking
approval of iclaprim from the U.S. Food & Drug Administration
(FDA) for the treatment of acute bacterial skin and skin structure
infections (ABSSSI). More than 3.6 million patients with ABSSSI are
hospitalised annually in the U.S. It is estimated that up to 26% of
hospitalized ABSSSI patients have renal impairment.
The Company also has plans to develop iclaprim
for hospital acquired bacterial pneumonia (HABP), including
ventilator associated bacterial pneumonia (VABP), as there is a
high unmet need for new therapies in this indication. A Phase
2 trial in patients with HABP has been successfully completed and a
Phase 3 trial is being planned. Additionally, iclaprim has been
granted orphan drug designation by the FDA for the treatment of
Staphylococcus aureus lung infections in patients with cystic
fibrosis and is in preclinical development for this indication.
Iclaprim has received Qualified Infectious
Disease Product (QIDP) designation from the FDA together with Fast
Track status for the ABSSSI indication. If approved for the ABSSSI
indication as a New Chemical Entity, iclaprim will be eligible for
10 years of market exclusivity in the U.S. from the date of first
approval, under the Generating Antibiotic Incentives Now Act (the
GAIN Act). In Europe, 10 years of market exclusivity is
anticipated. Motif is also building a patent estate to
provide additional protection for iclaprim and has two U.S. method
of use patents issued that will expire in 2037.
Forward-Looking Statements
This press release contains forward-looking
statements. Words such as “expect,” “believe,” “intend,” “plan,”
“continue,” “may,” “will,” “anticipate,” and similar expressions
are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause Motif
Bio’s actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Motif Bio
believes that these factors include, but are not limited to, (i)
the timing, progress and the results of clinical trials for Motif
Bio’s product candidates, (ii) the timing, scope or likelihood of
regulatory filings and approvals for Motif Bio’s product
candidates, (iii) Motif Bio’s ability to successfully commercialise
its product candidates, (iv) Motif Bio’s ability to effectively
market any product candidates that receive regulatory approval, (v)
Motif Bio’s commercialisation, marketing and manufacturing
capabilities and strategy, (vi) Motif Bio’s expectation regarding
the safety and efficacy of its product candidates, (vii) the
potential clinical utility and benefits of Motif Bio’s product
candidates, (viii) Motif Bio’s ability to advance its product
candidates through various stages of development, especially
through pivotal safety and efficacy trials, (ix) Motif Bio’s
estimates regarding the potential market opportunity for its
product candidates, (x) Motif Bio’s ability to raise additional
capital to sustain its operations and pursue its strategy and (xi)
the factors discussed in the section entitled “Risk Factors” in
Motif Bio’s Annual Report on Form 20-F filed with the SEC on April
10, 2018, which is available on the SEC’s web site, www.sec.gov.
Motif Bio undertakes no obligation to update or revise any
forward-looking statements.
Motif Bio (NASDAQ:MTFB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Motif Bio (NASDAQ:MTFB)
Historical Stock Chart
From Oct 2023 to Oct 2024